Exosomes Early Promise

Exosomes Early Promise

While exosome therapy is a burgeoning field, there are currently no FDA approved exosome treatments as more studies are needed to confirm the safety and efficacy of such products.

read more
Expanded Access

Expanded Access

Expanded access is an FDA program that under certain conditions allows the use of an investigational new drug (IND) to treat a patient with a serious or life-threatening disease outside of a clinical trial.

read more
Eligibility for Right to Try

Eligibility for Right to Try

The Right to Try Act provides a new channel for eligible patients to request access to investigational drugs outside of their ongoing clinical trial.

read more
Stem Cells and Anti-Aging

Stem Cells and Anti-Aging

As the science of aging expands its knowledge of all the changes and challenges of aging, the use of stem cells for anti-aging will become one of the standards of care.

read more
Who Named Mesenchymal Stem Cells?

Who Named Mesenchymal Stem Cells?

Over thirty years ago Dr. Arnold Caplan coined the term MSCs and since then there have been thousands of clinical trials involving the use of adult stem cells.

read more
The Jury is Still Out on Exosomes

The Jury is Still Out on Exosomes

Though exosomes have shown some promise in the treatment of various diseases, more research is needed to determine the safety and efficacy of these products.

read more